Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$53000.0.

  • Aligos Therapeutics' Cash from Financing Activities fell 122500.0% to -$53000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $101.6 million, marking a year-over-year increase of 1521.08%. This contributed to the annual value of $355000.0 for FY2024, which is 9959.81% down from last year.
  • According to the latest figures from Q3 2025, Aligos Therapeutics' Cash from Financing Activities is -$53000.0, which was down 122500.0% from -$177000.0 recorded in Q2 2025.
  • In the past 5 years, Aligos Therapeutics' Cash from Financing Activities registered a high of $101.7 million during Q1 2025, and its lowest value of -$177000.0 during Q2 2025.
  • Its 5-year average for Cash from Financing Activities is $14.2 million, with a median of $83000.0 in 2022.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 180000.0% in 2024, then skyrocketed by 53558421.05% in 2025.
  • Aligos Therapeutics' Cash from Financing Activities (Quarter) stood at $552000.0 in 2021, then plummeted by 78.08% to $121000.0 in 2022, then soared by 72574.38% to $87.9 million in 2023, then plummeted by 99.89% to $97000.0 in 2024, then plummeted by 154.64% to -$53000.0 in 2025.
  • Its Cash from Financing Activities was -$53000.0 in Q3 2025, compared to -$177000.0 in Q2 2025 and $101.7 million in Q1 2025.